A chemical view of oligonucleotides for exon skipping and related drug applications

Nucleic Acid Therapeutics

Volumn 24, Issue 1, 2014, Pages 37-47

  Järver, Peter ^a   O'Donovan, Liz ^a   Gait, Michael J ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHOLINO OLIGONUCLEOTIDE; OLIGONUCLEOTIDE; PEPTIDE NUCLEIC ACID; PHOSPHOROTHIOIC ACID;

CHEMISTRY; ENDOCYTOSIS; EXON; EXON SKIPPING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW;

ANIMALS; EXONS; HUMANS; MOLECULAR STRUCTURE; MORPHOLINOS; OLIGONUCLEOTIDES, ANTISENSE; PEPTIDE NUCLEIC ACIDS; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; TARGETED GENE REPAIR;

EID: 84893541929     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2013.0454     Document Type: Review

References (91)

1. AARTSMA-RUS, A., KAMAN, W.E., BREMMER-BOUT, M., JANSON, A.A.M., DEN DUNNEN, J.T., VAN OMMEN, G.B., and VAN DEUTEKOM, J.C.T. (2004). Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther. 11, 1391-1398.
2. ABES, S., TURNER, J.J., IVANOVA, G.D., OWEN, D., WILLIAMS, D., ARZUMANOV, A., CLAIR, P., GAIT, M.J., and LEBLEU, B. (2007). Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acid Res. 35, 4495-4502.
3. ALAM, M.R., DIXIT, V., KANG, H., LI, Z.-B., CHEN, X., TREJO, J., FISHER, M., and JULIANO, R.L. (2008). Intracellular delivery of an anionic antisense oligonucleotide via receptor mediated endocystosis. Nucleic Acids Res. 36, 2764-2776.
4. ALTER, J., LOU, F., RABINOWITZ, A., YIN, H., ROSENFELD, J., WILTON, S.D., PARTRIDGE, T.A., and LU, Q.L. (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nature Med. 12, 175-177.
5. AOKI, Y., YOKOTA, T., NAGATA, T., NAKAMURA, A., TANIHATA, J., SAITO, T., DUGUEZ, S.M.R., NAGARAJU, K., HOFFMAN, E.P., PARTRIDGE, T., et al. (2012). Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc. Nat. Acad. Sci. U. S. A. 109, 13763-13768.
6. ARZUMANOV, A., WALSH, A.P., RAJWANSHI, V.K., KUMAR, R., WENGEL, J., and GAIT, M.J. (2001). Inhibition of HIV-1 Tat-dependent trans-activation by steric block chimeric 2'-O-methyl/LNA oligoribonucleotides. Biochemistry 40, 14645-14654.
7. BASSI, E., FALZARANO, S., FABRIS, M., GUALANDI, F., MERLINI, L., VATTEMI, D., PERRONE, D., MARCHESI, E., SABATELLI, P., SPARNACCI, K. et al. (2012). Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice. J. Biomed. Biotechnol. doi:10.1155/2012/897076.
8. BETTS,C., SALEH, A.F.,ARZUMANOV,A.A.,HAMMOND, S.M., GODFREY, C.,COURSINDEL,T.,GAIT, M.J., andWOOD,M.J.A. (2012). Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity forDMD treatment. Mol. Ther. Nucl. Acids 1, e38.
9. CIRAK, S., ARECHAVALA-GOMEZA, V., GUGLIERI, M., FENG, L., TORELLI, S., ANTHONY, K., ABBS, S., GARRALDA, M.E., BOURKE, J., WELLS, D.J., et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open label, phase 2, dose-escalation study. Lancet 378, 595-605.
10. DAVIS, S., PROPP, S., FREIER, S.M., JONES, L.E., SERRA, M.J., KINBERGER, G., BHAT, B., SWAYZE, E.E., BENNETT, C.F., and ESAU, C. (2009). Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res. 37, 70-77.
11. DEUSS, P., ARZUMANOV, A., WILLIAMS, D., and GAIT, M.J. (2013). Parallel synthesis and splicing redirection activity of cell-penetrating peptide conjugate libraries of a PNA cargo. Org. Biomol. Chem. 11, 7621-7630.
12. DISTERER, P., AL-SHAWI, R., ELLMERICH, S., WADDINGTON, S.N., OWEN, J.S., SIMONS, J.P., and KHOO, B. (2013). Exon skipping of hepatic ApoB pre-mRNA with spliceswitching oligonucleotides reduces LDL cholesterol in vivo. Mol Ther. 21, 602-609.
13. EGHOLM, M., BUCHARDT, O., CHRISTENSEN, L., BEHRENS, C., FREIER, S.M., DRIVER, D.A., BERG, R.H., KIM, S.K., NORDEN, B., and NIELSEN, P. (1993). PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen bonding rules. Nature 365, 566-568.
14. EGHOLM, M., BUCHARDT, O., NIELSEN, P.E., and BERG, R.H. (1992). Peptide nucleic acids (PNA). Oligonucleotide analogues with an achiral backbone. J. Amer. Chem. Soc. 114, 1895-1897.
15. ELAYADI, A.N., BRAASCH, D.A., and COREY, D.R. (2002). Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry 41, 9973-9981.
16. FERLINI, A., SABATELLI, P., FABRIS, M., BASSI, E., FALZARANO, S., VATTEMI, D., GUALANDI, F., MARALDI, N.M., MERLINI, L., SPARNACCI, K., et al. (2010). Dystrophin restoration in skeletal, heart and skin arrector pili smooth msucle of mdx mice by ZM2 NP-AON complexes. Gene Ther. 17, 432-438.
17. FLETCHER, S., HONEYMAN, K., FALL, A.M., HARDING, P.L., JOHNSEN, R.D., and WILTON, S.D. (2006). Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med. 8, 207-216.
18. GOEMANS, N.M., TULINIUS, M., VAB DEN AKKER, J.T., BURM, B.E., EKHART, P.F., HEUVELMANS, N., HOLLING, T., JANSON, A.A., PLATENBURG, G.J., SIPKENS, J.A., et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. New Engl. J. Med. 364, 1513-1522.
19. GONZÁ LEZ-BARRIGA, A., MULDERS, S.A.M., VAN DE GIESSEN, J., HOOIJER, J.D., BIJL, S., VAN KESSEL, I.D.G., VAN BEERS, J., VAN DEUTEKOM, J.C., FRANSEN, J.A.M., WIERINGA, B., et al. (2013). Design and analysis of effects of triplet repeat oligonucleotides in cell models for myotonic dystrophy. Mol. Ther. Nucl. Acids 2, e81.
20. GOTO, M., SAWAMURA, D., NISHIE, W., SAKAI, K., MCMILLAN, J.R., AKIYAMA, M., and SHIMIZU, H. (2006). Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients. J. Invest. Dermatol. 126, 2614-2620.
21. GOYENVALLE, A., BABBS, A., AVRIL, A., GRIFFITHS, G., DUGOVIC, B., DAVIES, K.E., LEUMANN, C., and GARCIA, L. (2013). Tricyclo-DNA: a promising chemistry for the synthesis of antisense molecule for splice switching approaches in DMD. Neuromuscul. Disord. 22, 907.
22. GRAZIEWICZ, M.A., TARRANT, T.K., BUCKLEY, B., ROBERTS, J., FULTON, L., HANSEN, H.F., ∅RUM, H., KOLE, R., and SAZANI, P. (2008). An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models. Mol. Ther. 16, 1316-1322.
23. HEEMSKERK, H.A., DE WINTER, C.L., DE KIMPE, S.J., VAN KUIK-ROMEIJN, P., HEUVELMANS, N., PLATENBURG, G., VAN OMMEN, G.B., VAN DEUTEKOM, J.C., and AARTSMA-RUS, A. (2009). In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J. Gene Med. 11, 257-266.
24. HUA, Y., SAHASHI, K., HUNG, G., RIGO, F., PASSINI, M.A., BENNETT, C.F., and KRAINER, A.R. (2010). Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 24, 1634-1644.
25. IVANOVA, G.D., ARZUMANOV, A., ABES, R., YIN, H., WOOD, M.J.A., LEBLEU, B., and GAIT, M.J. (2008). Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res. 36, 6418-6428.
26. IVANOVA, G.D., REIGADAS, S., ITTIG, D., ARZUMANOV, A., ANDREOLA, M.-L., LEUMANN, C., TOULMÉ , J.J., and GAIT, M.J. (2007). Tricyclo-DNA containing oligonucleotides as steric block inhibitors of Human Immunodeficiency Virus Type 1 Tat-dependent trans-activation and HIV-1 infectivity. Oligonucleotides 17, 54-65.
27. JEARAWIRIYAPAISARN, N., MOULTON, H.M., BUCKLEY, B., ROBERTS, J., SAZANI, P., FUCHAROEN, S., IVERSEN, P.L., and KOLE, R. (2008). Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol. Ther. 16, 1624-1629.
28. KARRAS, J.G., MAIER, M.A., WATT, A., and MANOHARAN, M. (2001). Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-5 receptor-a chain. Biochemistry 40, 7853-7859.
29. KARRAS, J.G., MCKAY, R.A., DEAN, N.M., and MONIA, B.P. (2000). Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression throygh antisense oligonucleotide-mediated redirection of pre-mRNA splicing. Mol. Pharmacol. 58, 380-387.
30. KOEBIS, M., KIYATAKE, T., YAMAURA, H., NAGANO, K., HIGASHIHARA, M., SONOO, M., HAYASHI, Y., NEGISHI, Y., ENDO-TAKAHASHI, Y., YANAGIHARA, D., et al. (2013). Ultrasound-enhanced delivery of morpholino with bubble liposomes ameliorates the myotonia of myotonic dystrophy model mice. Sci. Rep. 3, doi:10.1038/srep02242.
31. KOLE, R., KRAINER, A.R., and ALTMAN, S. (2012). RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nature Rev. 11, 125-140.
32. KOSHKIN, A.A., SINGH, S.K., NIELSEN, P., RAJWANSHI, V.K., KUMAR, R., MELDGAARD, M., OLSEN, C.E., and WENGEL, J. (1998). LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 54, 3607-3630.
33. KURRECK, J. (2008). Therapeutic oligonucleotides. (Royal Society of Chemistry, Cambridge), pp. 1-343.
34. LANFORD, R.E., HILDEBRANDT-ERIKSEN, E.S., PETRI, A., PERSSON, R., LINDOW, M., MUNK, M.E., KAUPPINEN, S., and ∅RUM, H. (2010). Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201.
35. LEBLEU, B., MOULTON, H.M., ABES, R., IVANOVA, G.D., ABES, S., STEIN, D.A., IVERSEN, P.L., ARZUMANOV, A., and GAIT, M.J. (2008). Cell penetrating peptide conjugates of steric block oligonucleotides. Adv. Drug Deliv. Rev. 60, 517-529.
36. LEGER, A.J., MOSQUEA, L.M., CLAYTON, N.P., WU, I.-H., WEEDEN, T., NELSON, C.A., PHILLIPS, L., ROBERTS, E., PIEPENHAGEN, P.A., CHENG, S.H., et al. (2013). Systemic delivery of a peptide-linked morpholino oligonucleotide neutraiizes mutant RNA toxicity in a mouse model of myotonic dystrophy. Nucl. Acid Ther. 23, 109-117.
37. LENNOX, K.A., OWCZARZY, R., THOMAS, D.M., WALDER, J.A., and BEHLKE, M.A. (2013). Improved performance of anti-miRNA oligonucleotides using a novel non-nucleotide modifier. Mol. Ther. Nucl. Acids 2, e117.
38. LIGHTFOOT, H.L., and HALL, J. (2012). Target mRNA inhibition by oligonucleotide drugs in man. Nucl. Acids Res. 40, 10585-10595.
39. LU, Q.L., RABINOWITZ, A., CHEN, Y.C., YOKOTA, T., YIN, H.F., ALTER, J., JADOON, A., BOU-GHARIOS, G., and PARTRIDGE, T. (2005). Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in bodywide skeletal muscles. Proc. Natl. Acad. Sci. U. S. A. 102, 198-203.
40. MATSUKURA, M., SHINOZUKA, K., ZON, G., MITSUYA, H., REITZ, M., COHEN, J., and BRODER, S. (1987). Phosphorothioate analogs of oligodeoxyribonucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci. U. S. A. 84, 7706-7710.
41. MENDELL, J., RODINO-KLAPAC, L.R., SAHENK, Z., ROUSH, K., BIRD, L., LOWES, L.P., ALFANO, L., GOMEZ, A.M., LEWIS, S., KOTA, J., et al. (2013). Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 66, doi: 10.1002/ana.23982.
42. MING, X., ALAM, M.R., FISHER, M., YAN, Y., CHEN, X., and JULIANO, R.L. (2010). Intracellular delivery of an antisense oligonucleotide via endocytosis of a G-protein coupled receptor. Nucl. Acids Res. 38, doi:10.1093/nar/gkq534
43. MOULTON, H.M., and MOULTON, J.D. (2008). Antisense morpholino oligomers and their peptide conjugates. In: Therapeutic Oligonucleotides. J. Kurreck, ed. (Royal Society of Chemistry, Cambridge). pp 43-79.
44. MOULTON, H.M., and MOULTON, J.D. (2010). Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim. Biophys. Acta 12, 2296-2303.
45. MULDERS, S.A.M., VAN DEN BROECK, W.J.A.A., WHEELER, T., CROES, H.J.E., VAN KUIK-ROMEIJN, P., DE KIMPE, S.J., FURLING, D., PLATENBURG, G.J., GOURDON, G., THORNTON, C.A., et al. (2009). Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc. Nat. Acad. Sci. U. S. A. 106, 13915-13920.
46. MUNTONI F., WOOD M.J.A. (2011). Targeting RNA to treat neuromuscular disease. Nat. Rev. Drug Discov. 10, 621-637.
47. MURRAY, S., ITTIG, D., KOLLER, E., BERDEJA, A., CHAPPELL, A., PRAKASH, T.P., NORRBOM, M., SWAYZE, E.E., LEUMANN, C., and SETH, P.P. (2012). TricycloDNAmodified oligo-2'-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues: a comparative study of oligonucleotide length, design and chemistry. Nucl. Acids Res. 40, 6135-6143.
48. OBAD, S., DOS SANTOS, C., PETRI, A., HEIDENBLAD, M., BROOM, O., RUSE, C., FU, C., LINDOW, M., STENVANG, J., STRAARUP, E., et al. (2011). Silencing of microRNA families by seed targeting tiny LNAs. Nat. Genet. 43, 371-378.
49. OBIKA, S., MORIO, K.-I., HARI, Y., and IMANISHI, T. (1999). Preparation and properties of 2¢,5¢-linked oligonucleotide analogues containing 3¢-O,4¢-C-methyleneribonucleosides. Biorg. Med. Chem. Lett. 9, 515-518.
50. OSMAN, E.Y., YEN, P.-F., and LORSON, C.L. (2012). Bifunctional RNAs targeting the intronic splicing silencer N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy. Mol. Ther. 20, 119-126.
51. PASSINI, M.A., BU, J., RICHARDS, A.M., KINNECOM, C., SARDI, S.P., STANEK, L.M., HUA, Y., RIGO, F., MATSON, J., HUNG, G., et al. (2011). Antisense oligonucleotide delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 3, 72ra18.
52. PORENSKY, P.N., MITRPANT, C., MCGOVERN, V.L., BEVAN, A.K., FOUST, K.D., KASPAR, B.K., WILTON, S.D., and BURGHES, A.H.M. (2012). A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mice. Hum. Mol. Genet. 21, 1625-1638.
53. RIGO, F., HUA, Y., CHUN, S.J., PRAKASH, T.P., KRAINER, A.R., and BENNETT, C.F. (2012). Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing. Nat. Chem. Biol. 8, 555-561.
54. ROBERTS, J., PALMA, E., SAZANI, P., ∅RUM, H., CHO, M., and KOLE, R. (2006). Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol. Ther. 14, 471-475.
55. SAID HASSANE, F., SALEH, A.F., ABES, R., GAIT, M.J., and LEBLEU, B. (2010). Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell. Mol. Life Sci. 67, 715-726.
56. SAZANI, P., GEMIGNANI, F., KANG, S.-H., MAIER, M.A., MANOHARAN, M., PERSMARK, M., BORTNER, D., and KOLE, R. (2002). Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotech. 20, 1228-1233.
57. SAZANI, P., KANG, S.-H., MAIER, M.A., WEI, C., DILLMAN, J., SUMMERTON, J., MANOHARAN, M., and KOLE, R. (2001). Nuclear antisense effects of neutral, anionic and cationic analogs. Nucleic Acids Res. 29, 3965-3974.
58. SAZANI, P., VAN NESS, K.P., WELLER, D.L., POAGE, D.W., PALYADA, K., and SHREWSBURY, S.B. (2011). Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of Duchenne muscular dystrophy. Int. J. Toxicol. 30, 313-321.
59. SCHNELL, F.J., CRUMLEY, S., MOURICH, D.V., and IVERSEN, P.L. (2013). Development of novel bioanalytical methods to determine the effective concentrations of phosphorodiamidate morpholino oligomers in tissued and cells. Biores. Open Access 2, 61-66.
60. SETH, P.P., SIWKOWSKI, A.M., ALLERSON, C.R., VASQUEZ, G., LEE, S., PRAKASH, T.P., WANCEWICZ, E.V., WITCHELL, D., and SWAYZE, E.E. (2009). Short antisense oligonucleotides with novel 2'-4' conformationally restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem. 52, 10-13.
61. SHABANPOOR, F., and GAIT, M.J. (2013). Development of a general method for labelling peptide-morpholino oligonucleotide conjugates using alkyne-azide click chemistry. Chem. Commun. 49, 10260-10262.
62. SIRSI, S., SCHRAY, R.C., GUAN, X., LYKENS, N.M., WILLIAMS, J.H., ERNEY, M.L., and LUTZ, G.J. (2008). Funtionalized PEG-PEI copolymers complexed to exon-skipping oligonucleotides improve dystrophin expression in mdx mice. Hum. Gene Ther. 19, 795-806.
63. SIWKOWSKI, A.M., MALIK, L., ESAU, C.C., MAIER, M.A., WANCEWICZ, E.V., ALBERTSHOFER, K., MONIA, B.P., BENNETT, C.F., and ELDRUP, A.B. (2004). Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing. Nucleic Acids Res. 32, 2695-2706.
64. SKORDIS, L.A., DUNCKLEY, M.G., YUE, B., EPERON, I.C., and MUNTONI, F. (2003). Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc. Nat. Acad. Sci. U. S. A. 100, 4114-4119.
65. STRAARUP, E.M., FISKER, N., HEDTJÄ RN, M., LINDHOLM, M.W., ROSENBOHM, C., AARUP, V., HANSEN, H.F., ∅RUM, H., HANSEN, J.B.R., and KOCH, T. (2010). Short locked nucleic acid antisense oligonucleotides potently reduce apoliprotein B mRNA and serum cholesterol in mice and nonhuman primates. Nucleic Acids Res., 38, 7100-7111.
66. SUMMERTON, J., and WELLER, D. (1997). Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7, 187-195.
67. TAKAGI, M., YAGI, M., ISHIBASHI, K., TEAKESHIMA, Y., SURONO, A., MATSUO, M., and KOIZUMI, M. (2004). Design of 2'-O-Me RNA/ENA chimera oligonucleotides to induce exon skipping in dystrophin pre-mRNA. Nucleic Acids Symp. Series 48, 297-298.
68. TAKESHIMA, Y., YAGI, M., WADA, H., ISHIBASHI, K., NISHIYAMA, A., KAKUMOTO, M., SAKAEDA, T., SAURA, R., OKUMURA, K., and MATSUO, M. (2006). Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr. Res. 59, 690-694.
69. TANGANYIKA-DE-WINTER, C.L., HEEMSKERK, H., KARNAOUKH, T.G., VAN PUTTEN, M., DE KIMPE, S.J., VAN DEUTEKOM, J.C., and AARTSMA-RUS, A. (2012). Long-term exon skipping studies with 2'-O-methyl phosphorothioate antisense oligonucleotides in dystrophic mouse models. Mol. Ther. Nucl. Acids 1, e43.
70. VAN DEUTEKOM, J.C., DE KIMPE, S.J., and CAMPION, G.V. (2013). Antisense oligonucleotides as personalized medicine for Duchenne muscular dystrophy. Drug Discov. Today Ther Strateg. doi: org/10.1016/j.ddstr.2013.04.001.
71. VICKERS, T.A., ZHANG, H., GRAHAM, M.J., LEMONIDIS, K.M., ZHAO, C., and DEAN, N.M. (2006). Modification of MyD88 mRNA splicing and inhibition of IL-1 signaling in cell culture and in mice with a 2'-Omethoxyethyl-modified oligonucleotide. J. Immunol. 176, 3652-3661.
72. WANCEWICZ, E.V., MAIER, M.A., SIWKOWSKI, A.M., ALBERTSHOFER, K., WINGER, T.M., BERDEJA, A., GAUS, H., VICKERS, T.A., BENNETT, C.F., MONIA, B.P., et al. (2010). Peptide nucleic acids conjugated to short basic peptide show improved pharmacokinetics and antisense activity in adipose tissue. J. Med. Chem. 53, 3919-3926.
73. WANG, M., WU, B., LU, P., CLOER, C., TUCKER, J.D., and LU, Q. (2013). Polyethylenimine-modified pluronics (PCMs) improve morpholino oligomer delivery in cell culture and dystrophic mdx mice. Mol. Ther. 21, 210-216.
74. WHEELER, T.M., LEGER, A.J., PANDEY, S.K., MACLEOD, A.R., NAKAMORI, M., CHENG, S.H., WENTWORTH, B.M., BENNETT, C.F., and THORNTON, C.A. (2012). Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488, 111-115.
75. WHEELER, T.M., SOBCZAK, K., LUECK, J.D., OSBORNE, R.J., LIN, X., DIRKSEN, R.T., and THORNTON, C.A. (2009). Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325, 336-339.
76. WIDRICK, J.J., JIANG, S., CHOI, S.J., KNUTH, S.T., and MORCOS, P.A. (2011). An octaguanidine-morpholino oligoconjugate improves muscle function of mdx mice. Muscle Nerve 44, 563-570.
77. WILLIAMS, J.H., SCHRAY, R.C., PATTERSON, C.A., AYITEY, S.O., TALLENT, M.K., and LUTZ, G.J. (2009). Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J. Neurosci. 29, 7633-7638.
78. WU, B., BENRASHID, E., MALIK, S., ASHAR, J., DORAN, T.J., and LU, Q.L. (2010). Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther. 17, 132-140.
79. WU, B., LI, Y.-F., MORCOS, P.A., DORAN, T.J., LU, P., and LU, Q.L. (2009). Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol. Ther. 17, 864-871.
80. WU, B., LU, P., CLOER, C., SHABAN, M., GREWAL, S., MILAZI, S., SHAH, S.N., MOULTON, H.M., and LU, Q.L. (2012). Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino. Am. J. Pathol. 181, 392-400.
81. WU, B., MOULTON, H.M., IVERSEN, P.L., JUANG, J., LI, J., SPURNEY, C.F., SALI, A., GUERRON, A.D., NAGARAJU, K., DORAN, T., et al. (2008). Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modifies morpholino oligomer. Proc. Natl. Acad. Sci. U. S. A. 105, 14814-14819.
82. YAGI, M., TAKESHIMA, Y., SURONO, A., TAKAGI, M., KOIZUMI, M., and MATSUO, M. (2004). Chimeric RNA and 2'-O, 4'-C-ethylene-bridged nucleic acids have stronger activity than phosphorothioate oligodeoxynucleotyides in induction of exon 19 skipping in dystrophin mRNA. Oligonucleotides 14, 33-40.
83. YAMADA, T., OKANIWA, N., SANEYOSHI, H., OHKUBO, A., SEIO, K., NAGATA, T., AOKI, Y., TAKEDA, S., and SEKINE, M. (2011). Synthesis of 2'-O-[2-(N- methylcarbamoyl)ethyl] ribonucleosides using oxa-Michael reaction and chemical and biological properties of oligonucleotide derivatives incoprorating these modified ribonucleosides. J. Org. Chem. 76, 3042-3053.
84. YANG, L., NIU, H., GAO, X., WANG, Q., HAN, G., CAO, L., CAI, C., WELLER, J., and YIN, H. (2013). Effective exon skipping and dystrophin restoration by 2'-O-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice. PloS One 8, e61584.
85. YILMAZ-ELIS, A.S., AARTSMA-RUS, A., T' HOEN, P.A.C., SAFDAR, H., BREUKEL, C., VAN VLIJMEN, B.J.M., VAN DEUTEKOM, J.C., DE KIMPE, S.J., VAN OMMEN, G.B., and VERBEEK, J.S. (2013). Inhibition of IL-1 signalling by antisense oligonucleotide-mediated exon skipping of IL-1 receptor accessory protein (IL-1 RAcP). Mol. Ther. Nucleic Acids 2, e66.
86. YIN, H., BETTS, C., SALEH, A.F., IVANOVA, G.D., LEE, H., SEOW, Y., KIM, D., GAIT, M.J., and WOOD, M.J.A. (2010). Opimization of peptide nucleic acids antisense olignucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol. Ther. 18, 819-827.
87. YIN, H., LU, Q., and WOOD, M. (2008a). Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol. Ther. 16, 38-45.
88. YIN, H., MOULTON, H.M., SEOW, Y., BOYD, C., BOUTILIER, J., IVERSEN, P., and WOOD, M.J.A. (2008b). Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum. Mol. Gen. 17, 3909-3918.
89. YIN, H., SALEH, A.F., BETTS, C., CAMELLITI, P., SEOW, Y., ASHRAF, S., ARZUMANOV, A., HAMMOND, S., MERRITT, T., GAIT, M.J., et al. (2011). Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol. Ther. 19, 1295-1303.
90. YOKOTA, T., NAKAMURA, A., NAGATA, T., SAITO, T., KOBAYASHI, M., AOKI, Y., ECHIGOYA, Y., PARTRIDGE, T., HOFFMAN, E.P., and TAKEDA, S. (2012). Extensive and prolonged restoration of dystrophin expression with Vivomorpholino-mediated multiple exon skipping in dystrophic dogs. Nucl. Acid Ther. 22, 306-315.
91. ZHOU, H., JANGHRA, N., MITRPANT, C., DICKINSON, R.L., ANTHONY, K., PRICE, L., EPERON, I.C., WILTON, S.D., MORGAN, J., and MUNTONI, F. (2013). A novel morpholino oligomer targeting ISSN-1 improves rescue of severe spinal muscular atrophy transgenicmice. Hum. Gene Ther. 24, 331-342.